Women and peptide research gaps: trial representation, dose interpretation, and where the gap is closing

The historical imbalance

Until the 1990s, female participants were systematically underrepresented in many phase 1 pharmacokinetic and pharmacodynamic studies in the United States. Reasons cited at the time included concern about teratogenic exposure, hormonal-cycle variability, and statistical-power considerations on small studies. The downstream effect is that early dose-finding work for many older drug classes was anchored on male physiology.

The 1993 NIH Revitalization Act and subsequent FDA guidance changed the regulatory expectation, requiring meaningful inclusion of women in clinical trials and analyses by sex. Compliance and analytic rigor have improved substantially since, but coverage remains uneven across drug classes .

What this means for pharmacokinetics

• Body-size differences shift volume of distribution. Per-kilogram dosing helps but does not fully resolve clearance differences for some compounds.
• Hormonal-cycle effects on hepatic CYP enzymes can shift drug clearance for some classes, with the magnitude varying by enzyme and substrate.
• Population PK analyses on the modern GLP-1 trials include sex as a covariate; the published label sections summarize what those analyses found .
• Older non-peptide research compounds (some SARMs, older nootropics) have human PK data drawn from much smaller and more male-skewed samples, which is worth knowing when reading dose recommendations.

Where the gap is closing, and where it is not

Modern obesity and diabetes trials of GLP-1 and dual agonists have generally enrolled near-balanced sex distributions. STEP and SURMOUNT both included substantial female cohorts and reported sex-stratified subgroup analyses . That is a direct consequence of post-1993 regulatory expectations.

The gap remains visible in the older research-peptide and SARM literature, where original PK data come from small healthy-male cohorts. It also remains visible in long-term safety and pregnancy-exposure data, where postmarketing surveillance is the main lens and the data accumulate slowly. The FDA pregnancy and lactation labeling rule shapes how those data are presented in product labels .

Future work and live trials

The most useful path forward is sex-stratified subgroup analysis on every adequately powered trial, plus dedicated PK/PD work in female-only cohorts where it has not been done. ClinicalTrials.gov is a reasonable starting point for finding active trials by drug class and population .